Title: Drugs Treatment of Pain in Multiple Sclerosis
VOLUME: 2 ISSUE: 3
Author(s):Antonio Siniscalchi, Luca Gallelli and Giovambattista De Sarro
Affiliation:Clinical Pharmacology and Pharmacovigilance Unit, Chair of Pharmacology, Department of Experimental and Clinical Medicine, University “Magna Graecia” of Catanzaro,“Mater Domini” University Hospital, Via T. Campanella 115, 88100 Catanzaro,Italy.
Keywords:Psychogenic Pain, Trigeminal neuralgia, Carbamazepine, Phenytoin, Lamotrigine, Tricyclic antidepressants, Cannabinoids
Abstract: Pain is a frequent and disabling symptom among multiple sclerosis (MS) and it is estimated to occur in 55% to 65% of patients. The mechanism of pain in MS has not yet been defined, because it can result from somatic, visceral, emotional, or neurologic impairment. The importance of this classification is related to different medical approaches to treat the pain in MS patients. In the management of symptomatic pain, new therapeutic strategies are now available to represent a great opportunity improving the quality of life. The availability of newer drugs for symptomatic treatment of pain in MS indicates a need to pay attention to this problem.
